As we kick off 2025, Day One’s CEO Jeremy Bender took the stage at this year’s J.P. Morgan Healthcare Conference to reflect on the Company’s remarkable journey and to unveil our vision for the future. He highlighted the significant progress we’ve made, shared the exciting opportunities that lie ahead, and emphasized how we are poised to deliver life-changing medicines to patients faster, bolder, and with greater impact.

What began with inspiration driven by the urgent needs of children impacted by cancer, has in just six years, transformed Day One into a commercial-stage company with the FDA approval of our first commercial medicine, OJEMDA™ (tovorafenib). Our top priority in 2025 is to help even more patients impacted by a pediatric low-grade glioma (pLGG) diagnosis by increasing the breadth and depth of prescribers, establishing OJEMDA as the standard of care in the second-line setting, ensuring broader patient access, and working to make this treatment available to patients beyond the U.S. through our global partnership with Ipsen.

Driven by our dedication to patients, we’ve also made significant advancements in our pipeline, including progressing the global Phase 3 FIREFLY-2 trial of OJEMDA in front-line pLGG, which we expect to fully enroll in the first half of 2026. Additionally, our DAY301 program, a clinical-stage Antibody Drug Conjugate (ADC) targeting PTK7 in solid tumors for both adult and pediatric cancers, has just cleared the first cohort in the Phase 1a portion of the Phase 1a/b clinical trial. This ADC is designed to maximize the therapeutic window and has the potential to become a first-in-class option in addressing unmet needs in cancer care.

Finally, we will continue to invest in opportunities focused on targeted therapies that have the potential to have a substantive impact over existing medicines in the oncology space. Our achievements to date are a testament to the team’s deep expertise in oncology as well as our ability to identify and acquire high-potential programs. As we continue this journey, we are focused on ensuring that patients of all ages can look ahead from “Day One” to the future they’ve always envisioned.

To learn more about Day One’s vision for 2025 and beyond, as well as key highlights from JPM 2025, click here.